Metabolic

Semaglutide

GLP-1 receptor agonist (long-acting)

The GLP-1 analog that redefined cardiometabolic therapy.

Half-life

~ 165 hours (once-weekly dosing)

Mol. weight

4113.58 g/mol

Sequence

Modified GLP-1 analog (Aib⁸, Arg³⁴, C17 fatty-diacid side chain)

Discussions

1 threads

Overview

Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist developed for type 2 diabetes and chronic weight management. In the landmark SELECT trial (17,604 patients, ~40-month follow-up), once-weekly 2.4 mg semaglutide produced a 20% reduction in major adverse cardiovascular events (MACE) versus placebo in patients with overweight/obesity and established cardiovascular disease but without diabetes, alongside a 9.4% mean weight loss and a 22% reduction in a composite kidney endpoint.

Mechanism of action

Semaglutide is a modified GLP-1 analog engineered to resist DPP-4 degradation (via a C17 fatty-diacid side chain and amino-acid substitutions), extending its half-life to ~165 hours — enabling once-weekly dosing. It binds GLP-1 receptors on pancreatic beta cells to amplify glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and acts on brain satiety centers (including the arcuate nucleus) to reduce appetite. The net effect is improved glycemic control, sustained weight loss, and cardiometabolic benefit.

Researched benefits

Significant sustained weight loss (mean −9.4% at 104 weeks in SELECT)
20% reduction in major adverse cardiovascular events (MACE) vs placebo (SELECT)
22% reduction in a composite kidney endpoint; lowered UACR (SELECT)
Improved glycemic control (HbA1c reductions of ~1.4–1.8% across SUSTAIN trials)
Reduced appetite and cravings; ~38% reduction in high-sensitivity CRP (inflammation)

Considerations

Gastrointestinal side effects are common (nausea, vomiting, diarrhea, constipation)
Adverse-event discontinuation was ~16.6% vs ~8.2% placebo in SELECT
Loss of lean muscle mass can accompany rapid weight loss — resistance training advised
Rare risks: pancreatitis, gallbladder events; requires medical supervision

Key Academic Literature & Studies

Search more in PubMed

Peer-reviewed citations and clinical trials evaluating Semaglutide in scientific literature.

Articles & logs

Research2026-09-14·8 min

The SELECT Trial, Broken Down

17,604 patients, 20% fewer heart attacks — what the SELECT cardiovascular trial actually showed.

By Dr. M. Reyes

Protocol2026-09-05·6 min

Preserving Muscle During Weight Loss

Resistance training and protein intake strategies members use alongside GLP-1 research.

By Community Member

Research2026-07-30·5 min

The GLP-1 Receptor, Explained

A primer on how GLP-1 signaling controls insulin, satiety, and gastric emptying.

By Editorial Team